Sandramycin
(Synonyms: 山卓霉素) 目录号 : GC13794
An antitumor antibiotic
Cas No.:100940-65-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sandramycin is a cyclic depsipeptide antibiotic that was first isolated from cultured broth of a Nocardioides sp [1].
Sandramycin is an antitumor antibiotic. Sandramycin was closely related to the cyclic depsipeptides luzopeptins A, B, C and D. Sandramycin exhibited strong inhibition to the Gram-positive organisms Bacillus subtilis, Staphylococcus aureus and Streptococcusfaecalis. Its antimicrobial activity paralleled that which was observed for echinomycin and luzopeptin A [1]. Sandramycin was also a bifunctional DNA intercalator that strongly binds DNA and forms crosslinks between DNA molecules [2].
In transplantable mouse leukemia P388, Sandramycin was moderately active with values comparable to those for luzopeptin A. Injection of 2 mg/kg showed the best increase in life span over the controls (61%) [1].
References:
[1]. Matson JA, Bush JA. Sandramycin, a novel antitumor antibiotic produced by a Nocardioides sp. Production, isolation, characterization and biological properties. J Antibiot (Tokyo). 1989 Dec;42(12):1763-7.
[2]. Boger DL, Saionz KW. DNA binding properties of key sandramycin analogues: systematic examination of the intercalation chromophore. Bioorg Med Chem. 1999 Feb;7(2):315-21.
| Cas No. | 100940-65-6 | SDF | |
| 别名 | 山卓霉素 | ||
| 化学名 | N-[(3-hydroxy-2-quinolinyl)carbonyl]-D-seryl-(2S)-2-piperidinecarbonylglycyl-N-methylglycyl-N-methyl-L-valine, bimol. (5→1'3),(5'→13)-dilactone | ||
| Canonical SMILES | O=C([C@@H](COC([C@@H](N(C(CN(C(CNC([C@@](CCCC1)([H])N1C2=O)=O)=O)C)=O)C)C(C)C)=O)NC(C3=NC(C=CC=C4)=C4C=C3O)=O)N(CCCC5)[C@]5([H])C(NCC(N(CC(N([C@H](C(OC[C@H]2NC(C6=NC(C=CC=C7)=C7C=C6O)=O)=O)C(C)C)C)=O)C)=O)=O | ||
| 分子式 | C60H76N12O16 | 分子量 | 1221.3 |
| 溶解度 | DMF: soluble,DMSO: soluble,Ethanol: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8188 mL | 4.094 mL | 8.188 mL |
| 5 mM | 0.1638 mL | 0.8188 mL | 1.6376 mL |
| 10 mM | 0.0819 mL | 0.4094 mL | 0.8188 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。